Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DA-5210 (Dapagliflozin/Metformin) in Healthy Subjects (Fed State)
NCT05098275Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Oct 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Oct 2021; status: completed.
02
Drugs
dapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05098275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098275.